Tags

Type your tag names separated by a space and hit enter

Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series.
Curr Drug Saf. 2016; 11(1):102-3.CD

Abstract

Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed.

Authors+Show Affiliations

Department of Psychiatry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. patrasuravi@gmail.com.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

26391425

Citation

Patra, Suravi. "Tardive Dyskinesia and Covert Dyskinesia With Aripiprazole: a Case Series." Current Drug Safety, vol. 11, no. 1, 2016, pp. 102-3.
Patra S. Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series. Curr Drug Saf. 2016;11(1):102-3.
Patra, S. (2016). Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series. Current Drug Safety, 11(1), 102-3.
Patra S. Tardive Dyskinesia and Covert Dyskinesia With Aripiprazole: a Case Series. Curr Drug Saf. 2016;11(1):102-3. PubMed PMID: 26391425.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series. A1 - Patra,Suravi, PY - 2015/06/23/received PY - 2015/05/09/revised PY - 2015/09/17/accepted PY - 2015/9/23/entrez PY - 2015/9/24/pubmed PY - 2016/12/15/medline SP - 102 EP - 3 JF - Current drug safety JO - Curr Drug Saf VL - 11 IS - 1 N2 - Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed. SN - 2212-3911 UR - https://www.unboundmedicine.com/medline/citation/26391425/Tardive_Dyskinesia_and_Covert_Dyskinesia_with_Aripiprazole:_A_Case_Series_ L2 - http://www.eurekaselect.com/135092/article DB - PRIME DP - Unbound Medicine ER -